Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 48 articles: HTML format

Single Articles

September 2025
1. PACKER M, Lam CSP, Butler J, Zannad F, et al
   Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
   J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07341.
   PubMed     Abstract available
   
   
   
2. KRUMHOLZ HM, Inzucchi SE
   Beyond Adiposity: Embracing Complexity in Diabetes-Associated HFpEF.
   J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07385.
   PubMed    
   
   
   
3. KANG D, Choi KH, Kim JH
   Statins in Type 1 Diabetes: Bridging the Evidence Gap With Target Trial Emulation.
   J Am Coll Cardiol. 2025;86:810-812.
   PubMed    
   
   
   
4. BLAIS JE, Yan VKC, Chan EWY, Wong ICK, et al
   Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
   J Am Coll Cardiol. 2025;86:797-809.
   PubMed     Abstract available
   
   
   
5. PACKER M, Zile MR, Kramer CM, DiMaria JM, et al
   Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
   J Am Coll Cardiol. 2025;86:696-707.
   PubMed     Abstract available
   
   
   May 2025
6. AMINORROAYA A, Oikonomou EK, Biswas D, Jastreboff AM, et al
   Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.
   J Am Coll Cardiol. 2025;85:1858-1872.
   PubMed     Abstract available
   
   
   
7. HO JE, Chen ZZ, Lau ES
   Insulin Resistance and Diabetes in HFpEF: Bystander or Instigator?
   J Am Coll Cardiol. 2025;85:1789-1791.
   PubMed    
   
   
   
8. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
   Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction.
   J Am Coll Cardiol. 2025;85:1774-1788.
   PubMed     Abstract available
   
   
   April 2025
9. BORROWMAN JD, Huang X, Petito LC, Perak AM, et al
   Prepregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife.
   J Am Coll Cardiol. 2025;85:1536-1546.
   PubMed     Abstract available
   
   
   December 2024
10. SPERLING LS
    The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?
    J Am Coll Cardiol. 2024;84:2260-2263.
    PubMed    
    
    
    
11. GYLDENKERNE C, Kahlert J, Thrane PG, Olesen KKW, et al
    2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study.
    J Am Coll Cardiol. 2024;84:2251-2259.
    PubMed     Abstract available
    
    
    November 2024
12. SANTOS-PARDO I, Andersson Franko M, Nystrom T
    Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e321.
    PubMed    
    
    
    
13. LIU C, Li X, Cong H
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e319-e320.
    PubMed    
    
    
    
14. WARRAICH HJ, Patrick-Lake B, Saha A, Rashid L, et al
    Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration.
    J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028.
    PubMed    
    
    
    
15. PATEL KV, Chunawala Z, Verma S, Segar MW, et al
    Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study.
    J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10417.
    PubMed     Abstract available
    
    
    September 2024
16. MENTZ RJ, Kittipibul V
    Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle.
    J Am Coll Cardiol. 2024;84:1089-1091.
    PubMed    
    
    
    
17. BHATT AS, Bhatt DL, Steg PG, Szarek M, et al
    Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    J Am Coll Cardiol. 2024;84:1078-1088.
    PubMed     Abstract available
    
    
    
18. EVERETT BM, Wexler DJ
    Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease.
    J Am Coll Cardiol. 2024;84:918-920.
    PubMed    
    
    
    
19. KHERA R, Aminorroaya A, Dhingra LS, Thangaraj PM, et al
    Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    J Am Coll Cardiol. 2024;84:904-917.
    PubMed     Abstract available
    
    
    August 2024
20. MANUBOLU VS, Lakshmanan S, Kinninger A, Ahmad K, et al
    Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
    J Am Coll Cardiol. 2024;84:865-867.
    PubMed    
    
    
    
21. NEUEN BL, Ostrominski JW, Claggett B, Beldhuis IE, et al
    Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08155.
    PubMed    
    
    
    
22. PRATLEY RE, Tuttle KR, Rossing P, Rasmussen S, et al
    Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
    J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116.
    PubMed     Abstract available
    
    
    
23. NEUEN BL, Solomon SD
    Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:709-711.
    PubMed    
    
    
    
24. EDMONSTON D, Mulder H, Lydon E, Chiswell K, et al
    Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:696-708.
    PubMed     Abstract available
    
    
    
25. SHIN JI, Xu Y, Chang AR, Carrero JJ, et al
    Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    J Am Coll Cardiol. 2024;84:683-693.
    PubMed     Abstract available
    
    
    
26. OSTROMINSKI JW, Jemma Cho SM, Vaduganathan M, Honigberg MC, et al
    Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747.
    PubMed    
    
    
    
27. INZUCCHI SE, Arai AE
    Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    J Am Coll Cardiol. 2024;84:558-560.
    PubMed    
    
    
    
28. CHOWDHARY A, Thirunavukarasu S, Joseph T, Jex N, et al
    Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:540-557.
    PubMed     Abstract available
    
    
    July 2024
29. MARINHO LL, Everett BM, Aday AW, Visseren FLJ, et al
    Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.
    J Am Coll Cardiol. 2024;84:408-410.
    PubMed    
    
    
    
30. BABER U
    Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?
    J Am Coll Cardiol. 2024;84:273-275.
    PubMed    
    
    
    
31. GUGLIN M, Hillerson D
    Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities.
    J Am Coll Cardiol. 2024;84:244-246.
    PubMed    
    
    
    
32. LOPEZ J, Liu Y, Butler J, Del Prato S, et al
    Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.
    J Am Coll Cardiol. 2024;84:233-243.
    PubMed     Abstract available
    
    
    June 2024
33. VERMA S, Butler J, Borlaug BA, Davies M, et al
    Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
    J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445.
    PubMed     Abstract available
    
    
    
34. PINNEY SP, Costanzo MR
    As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
    J Am Coll Cardiol. 2024;83:2423-2425.
    PubMed    
    
    
    
35. LALA A, Mentz RJ, Santos-Gallego CG
    The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
    J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407.
    PubMed    
    
    
    May 2024
36. SANTOS-PARDO I, Andersson Franko M, Lagerqvist B, Ritsinger V, et al
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06933.
    PubMed     Abstract available
    
    
    April 2024
37. BONACA MP, Bhatt DL, Simon T, Fox KM, et al
    Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
    J Am Coll Cardiol. 2024;83:1627-1636.
    PubMed     Abstract available
    
    
    
38. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    PubMed     Abstract available
    
    
    
39. WONG ND, Fan W, Hu X, Ballantyne C, et al
    Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    J Am Coll Cardiol. 2024;83:1511-1525.
    PubMed     Abstract available
    
    
    
40. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    PubMed    
    
    
    
41. PACKER M
    SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
    J Am Coll Cardiol. 2024;83:1399-1402.
    PubMed    
    
    
    
42. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    PubMed     Abstract available
    
    
    
43. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    PubMed     Abstract available
    
    
    
44. COSTANZO MR, Januzzi JL
    Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    J Am Coll Cardiol. 2024;83:1307-1309.
    PubMed    
    
    
    
45. JANUZZI JL JR, Butler J, Del Prato S, Ezekowitz JA, et al
    Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613.
    PubMed     Abstract available
    
    
    March 2024
46. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e89.
    PubMed    
    
    
    
47. OHSHIRO Y
    Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e87.
    PubMed    
    
    
    
48. HANSEN MK, Olesen KKW, Gyldenkerne C, Thrane PG, et al
    Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    J Am Coll Cardiol. 2024;83:956-958.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.